The gut microbiome significantly influences immune responses and the efficacy of immune checkpoint inhibitors. We conducted a clinical trial (NCT04264975) combining an anti-programmed death-1 (PD-1) inhibitor with fecal microbiota transplantation (FMT) from anti-PD-1 responder in 13 patients with anti-PD-1-refractory advanced solid cancers. FMT induced sustained microbiota changes and clinical benefits in 6 of 13 patients, with 1 partial response and 5 stable diseases, achieving an objective response rate of 7.7% and a disease control rate of 46.2%. The clinical response correlates with increased cytotoxic T cells and immune cytokines in blood and tumors. We isolated Prevotella merdae Immunoactis from a responder to FMT, which stimulates T cell activity and suppresses tumor growth in mice by enhancing cytotoxic T cell infiltration. Additionally, we found Lactobacillus salivarius and Bacteroides plebeius may inhibit anti-tumor immunity. Our findings suggest that FMT with beneficial microbiota can overcome resistance to anti-PD-1 inhibitors in advanced solid cancers, especially gastrointestinal cancers.
Pubmed ID: 39059396 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This cocktail targets CD4, CD15, CD16, CD19, CD34, CD36, CD56, CD123, TCRγ/δ, CD235a (Glycophorin A)
View all literature mentionsThis cocktail targets CD8, CD14, CD15, CD16, CD19, CD36, CD56, CD123, TCR γ/δ, CD235a (Glycophorin A).
View all literature mentionsThis monoclonal targets NKG2A/C/E
View all literature mentionsThis monoclonal targets CD11b (Mac-1)
View all literature mentionsThis monoclonal targets NK-1.1
View all literature mentionsThis monoclonal targets Mouse CD8a
View all literature mentionsThis monoclonal targets TNF-alpha
View all literature mentionsThis monoclonal targets F4/80
View all literature mentionsThis monoclonal targets IFN-gamma
View all literature mentionsThis monoclonal targets CD25
View all literature mentionsThis monoclonal targets CD45R
View all literature mentionsThis monoclonal targets CD279
View all literature mentionsThis monoclonal targets CD62L
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets CD3
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets CD16/32
View all literature mentionsThis unknown targets FC receptors
View all literature mentionsThis monoclonal targets CD28
View all literature mentionsThis monoclonal targets CD3epsilon
View all literature mentionsThis monoclonal targets CD3
View all literature mentionsThis unknown targets
View all literature mentionsThis monoclonal targets PD-1 (CD279)
View all literature mentionsThis isotype control targets Trinitrophenol
View all literature mentionsMus musculus with name C57BL/6-Tg(TcraTcrb)1100Mjb/J from IMSR.
View all literature mentionslaboratory mouse with name BALB/cAnNCrlCrlj from MGI.
View all literature mentionslaboratory mouse with name C57BL/6NCrlCrlj from MGI.
View all literature mentionsCell line 4T1 is a Cancer cell line with a species of origin Mus musculus (Mouse)
View all literature mentionsCell line MC-38 is a Cancer cell line with a species of origin Mus musculus
View all literature mentions